Furthermore, in a study focusing on diabetic cardiomyopathy, the administration of SalB was found to increase the levels of vascular endothelial growth factor receptor 2 and vascular endothelial growth factor A in a dose-dependent manner by inhibiting insulin-like growth factor binding protein 3. Here, VEGFA is linked to diabetic cardiomyopathy.